Methods:
The authors explored non-major bleeding events among the 18,140 patients in the ARISTOTLE trial. Non-major bleeding included clinically relevant non-major (CRNM) bleeding and minor bleeding that was not preceded by a major bleeding event. Patients experiencing a non-major bleeding event were followed for any related clinical outcomes (major bleeding and mortality) during the remaining trial period.